Tests a herbal decoction added to usual care in diabetic kidney disease
Tests a herbal decoction added to usual care in adults with diabetic kidney disease.
Plain-language title generated from the registry record
Registry title: YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2
Key facts
- Where
- Beijing, Changchun, Guangzhou, and Tianjin, ChinaSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with type 2 diabetic kidney disease, reduced kidney function and a lot of protein in the urine.
- Age
- 18 to 80 years.
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetic kidney disease with eGFR from 30 up to but not including 60 ml/min/1.73m2, uACR of 300 mg/g or more, and a traditional Chinese medicine diagnosis of qi deficiency and collateral stasis syndrome.
- Earlier treatment
- People cannot be taking other traditional Chinese medicines with an effect on diabetic kidney disease. No other research drug or intervention within one month before consent.
- Biomarker or test result
- HbA1c between 7 and 10 % (53–86 mmol/mol). Blood pressure of 150/90 mmHg or lower.
Main reasons for not taking part
- Other clear kidney diseases, such as polycystic kidney disease, glomerulonephritis or kidney tumors
- Type 1 diabetes
- Malignant tumor within 5 years
- History of organ transplant or planned organ transplant, or immunodeficiency
- Maintenance dialysis for more than 2 weeks, or expected for more than 8 weeks
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07034807, who can take part
Where in China
- Dongzhimen HospitalBeijing, ChinaNo longer taking part
- Guang'anmen Hospital，China Academy of Chinese Medical SciencescancelBeijing, ChinaNo longer taking part
- The Affiliated Hospital to ChangChun University of Chinese MedicinecancelChangchun, ChinaNo longer taking part
- the First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou, ChinaNo longer taking part
- Tianjin Medical University Chu Hsien-I Memorial HospitalTianjin, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Liu Hongfang
- Trial code
- NCT07034807
- Record updated
- 24 June 2025
- Original description
Using the practical randomized controlled trial designed by Zelen, the subjects were randomly divided into the experimental group and the control group. The experimental group was given the traditional Chinese medicine prescription ' Shenzhuo Decoction ' ( composed of Astragalus membranaceus, Salvia miltiorrhiza, Leech, Raw Rhubarb, Epimedium, Motherwort ) + basic treatment ( including nutrition, lifestyle, hypoglycemic, hypotensive, lipid-lowering, control of other risk factors, etc. ), the control group was given basic treatment, a total of 1 year of drug intervention, followed up for 1 year.Read full original descriptionShow less
Evidence-based Evaluation of Yiqi Jiangzhuo Huoxue Tongluo Method in Delaying the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study 2
Using the practical randomized controlled trial designed by Zelen, the subjects were randomly divided into the experimental group and the control group. The experimental group was given the traditional Chinese medicine prescription ' Shenzhuo Decoction ' ( composed of Astragalus membranaceus, Salvia miltiorrhiza, Leech, Raw Rhubarb, Epimedium, Motherwort ) + basic treatment ( including nutrition, lifestyle, hypoglycemic, hypotensive, lipid-lowering, control of other risk factors, etc. ), the control group was given basic treatment, a total of 1 year of drug intervention, followed up for 1 year.
Inclusion: 1 In line with the diagnostic criteria of Western medicine type 2 DKD ; 2 18-80 years old, regardless of gender ; 3 30ml / min / 1.73m2 ≤ eGFR < 60ml / min / 1.73m2 ( eGFR was calculated according to CKD-EPI formula ) ; 4 In line with the diagnostic criteria of qi deficiency and collateral stasis syndrome in traditional Chinese medicine ; 5 hbA1c between 7-10 % ; 6 uACR ≥ 300mg / g; 7 blood pressure ≤ 150 / 90mmHg ; 8 signed the informed consent .
Exclusion: 1 Patients who are currently receiving other traditional Chinese medicines and Chinese patent medicines with DKD therapeutic effects ; 4 Patients who participated in any other research drug study and / or received or had received another research drug or intervention treatment ( within one month before signing the informed consent form ) ; 11 patients with maintenance dialysis > 2 weeks and / or expected maintenance dialysis > 8 weeks before treatment and patients who were judged by any researcher not suitable for inclusion in the trial; 2 combined with other clear renal diseases, such as polycystic kidney disease, glomerulonephritis, renal tumors ; 3 Patients with acute or chronic infection who needed treatment were judged by the researchers not suitable for inclusion in the study ; 5 patients who were allergic or contraindicated to the planned use of drugs ; 6 There are serious acute or chronic diseases that the major researchers believe may pose an excessive risk to the subjects, including : patients with cardiovascular, cerebrovascular, lung, blood, digestive tract, liver, kidney, neuropsychiatric or infectious diseases ; 7 Patients with a history of immunodeficiency, including patients with other acquired, congenital immunodeficiency diseases, or patients with a history of organ transplantation or planned organ transplantation ; 9 patients with a history of malignant tumors within 5 years ; 10 patients with type 1 diabetes ; 8 Women with positive pregnancy screening test or lactating or planning to get pregnant in the next 24 months. Female or male patients who were reluctant to use contraception throughout the study period .